



Speedcast – Journal Club

Seizoen 5

Episode 11 - 2025

Referenties

1. REMAP-CAP trial

Angus DC, Derde LPG, Al-Beidh F, Annane D, Arabi YM, Beane A, et al. Effect of hydrocortisone on mortality and organ support in patients with severe community-acquired pneumonia: the REMAP-CAP randomized clinical trial. *Intensive Care Med.* 2023;49

2. Air medical transport trauma study

Guyette FX, Brown JB, Zenati MS, et al. How many minutes matter? Association between time saved by air medical transport and survival in trauma patients. *J Trauma Acute Care Surg.* 2024

3. Platelet transfusion guidelines

Kaufman RM, Djulbegovic B, Gernsheimer T, Kleinman S, Tinmouth AT, Capocelli KE, et al. Platelet transfusion: 2025 AABB and ICTMG international clinical practice guidelines. *JAMA.* 2025

Strong Recommendations – [Condition: transfusion threshold; certainty of evidence]

- Non-bleeding hypoproliferative thrombocytopenia (active chemotherapy, allogeneic stem cell transplant (SCT)): **<10**; moderate
- Preterm neonates without major bleeding: **<25**; high
- Lumbar puncture: **<20**; moderate
- Dengue consumptive thrombocytopenia: **none**, possible harm; moderate

Conditional Recommendations – [Condition: threshold; certainty of evidence]

- Non-bleeding adult, hypoproliferative thrombocytopenia, autologous SCT or aplastic anemia: **none**, no prophylactic transfusion threshold; low to very low
- Adults consumptive thrombocytopenia from non-Dengue critical illness without major bleeding: **<10**; very low
- Adult central venous catheter, non-compressible site: **<10**; moderate to very low
- Adult interventional radiology procedure: **<20** if *low-risk*, **<50** if *high-risk* procedure; very low
- Adult major non-neuraxial surgery: **<50**; very low
- Non-thrombocytopenic, cardiovascular surgery, with no major hemorrhage, including CABG: **none**; very low
- Adult spontaneous or traumatic ICH with platelets >100, even if on antiplatelet agents: **none**; low to very low